When accessing the CDB site through an internal Novo Nordisk IP address, you will see "Your Location" as NN Internal instead of a country. This only applies to internal NN IP addresses. Thank you for your patience while the development team is upgrading this feature.

Your Location: USA

Help Join the Cause Submit Data

Bookmark and Share

Home > U.S. Initiative > Overview

Overview: Novo Nordisk U.S. Diabetes Barometer


The Diabetes Epidemic in the U.S.

How can America tackle its diabetes epidemic? Right now, the CDC estimates there are nearly 26 million people with diabetes, and an additional 79 million with prediabetes, putting them at high risk for developing type 2 diabetes.1


Measuring Progress in the Fight Against Diabetes

For Novo Nordisk, a global healthcare company committed to Changing Diabetes®, finding solutions begins with applying a mindset of “measure, share, and improve.” Globally, Novo Nordisk has developed the Diabetes Barometer as a framework for measuring progress in the fight against diabetes. What types of things are measured?

  • Public awareness of diabetes as a serious disease, and awareness of risk factors
  • Economic impact of diabetes
  • Appropriate screening to aid in early detection
  • Access to health care for people with diabetes and prediabetes
  • Clinical markers of diabetes treatment and quality

We encourage sharing these measurements as an important means to improve outcomes for people with diabetes and prediabetes, so that key stakeholders have a clear picture of the current quality of diabetes care and can learn about effective interventions to combat the diabetes epidemic.

We help stimulate dialogue and build a case for the importance of screening to identify people with undiagnosed diabetes and prediabetes; early intervention; and quality care for improved patient outcomes — all while working to raise diabetes higher on the U.S. national agenda.


Using Diabetes Data to Shape Public Policy

In the United States, Novo Nordisk has conducted original research that has resulted in new data on the societal, economic, and clinical impact of diabetes. We have used these data to help shape public policy:

  • Raising political awareness of diabetes
  • Promoting national investment in diabetes care to prevent complications of diabetes and improve quality of life for patients
  • Placing screening for diabetes higher on the national healthcare agenda
  • Advocating for community-based diabetes prevention programs
  • Inspiring others to adopt and follow best practice examples

U.S. Diabetes Research

Return To Top

Learn more about
current initiatives

The Novo Nordisk U.S. Diabetes Barometer focuses on educating policymakers and legislators about what is needed to effectively take on the many challenges posed by diabetes.

Learn More

Learn more about
future initiatives

Future Novo Nordisk U.S. Diabetes Barometer initiatives will continue to inform payers, legislators, and policymakers of the value of diabetes screening, treatment, and improved control.

Learn More

Learn more about
our research

Novo Nordisk is committed to calling for greater awareness and action around diabetes by showcasing our research efforts on changing diabetes.

Learn More

References:
1. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011.

Return To Top

For U.S. inquiries only, contact:
Rachel Bright
RLBR@novonordisk.com